Monte Rosa Therapeutics (NASDAQ:GLUE) COO Jennifer Champoux Sells 2,175 Shares

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) COO Jennifer Champoux sold 2,175 shares of the stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $20.00, for a total transaction of $43,500.00. Following the completion of the transaction, the chief operating officer owned 62,371 shares in the company, valued at $1,247,420. This represents a 3.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Monte Rosa Therapeutics Stock Performance

NASDAQ:GLUE traded up $0.22 during trading hours on Thursday, hitting $19.39. The stock had a trading volume of 1,184,250 shares, compared to its average volume of 696,389. Monte Rosa Therapeutics, Inc. has a one year low of $3.90 and a one year high of $25.77. The company has a market cap of $1.64 billion, a price-to-earnings ratio of -13.10 and a beta of 1.62. The business’s 50 day moving average is $18.12 and its 200-day moving average is $18.16.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. The firm had revenue of $4.21 million during the quarter, compared to the consensus estimate of $10.95 million. On average, sell-side analysts anticipate that Monte Rosa Therapeutics, Inc. will post -1.23 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. JPMorgan Chase & Co. upped their target price on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Wall Street Zen downgraded shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Guggenheim lowered their target price on shares of Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a research note on Wednesday, March 18th. Weiss Ratings raised shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Finally, Wells Fargo & Company lowered their price objective on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research report on Wednesday, March 18th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Monte Rosa Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $32.50.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in GLUE. State Street Corp grew its position in Monte Rosa Therapeutics by 148.9% in the fourth quarter. State Street Corp now owns 2,107,480 shares of the company’s stock valued at $33,045,000 after purchasing an additional 1,260,707 shares in the last quarter. MPM Bioimpact LLC bought a new position in Monte Rosa Therapeutics in the fourth quarter valued at $18,399,000. AQR Capital Management LLC grew its position in Monte Rosa Therapeutics by 459.4% in the second quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock valued at $5,791,000 after purchasing an additional 1,054,406 shares in the last quarter. Braidwell LP bought a new position in Monte Rosa Therapeutics in the fourth quarter valued at $14,870,000. Finally, Vestal Point Capital LP bought a new position in Monte Rosa Therapeutics in the third quarter valued at $5,928,000. Institutional investors own 79.96% of the company’s stock.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.